Response to ranibizumab therapy in neovascular AMD- An evaluation of good and bad responders

Klinische Monatsblatter fur Augenheilkunde

Volumn 227, Issue 4, 2010, Pages 227-248

  Menghini, M ^a   Kurz Levin, M M ^a   Amstutz, C ^a   Michels, S ^a   Windisch, R ^a   Barthelmes, D ^a   Sutter, F Kp ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

AMD; Lucentis; MARINA; Response; Treatment

Indexed keywords

RANIBIZUMAB; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SEX DIFFERENCE; SEX RATIO; SWITZERLAND; UNIVERSITY HOSPITAL; DOSE RESPONSE; PREVALENCE; PROGNOSIS; RETINA MACULA DEGENERATION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SWITZERLAND; TREATMENT OUTCOME;

EID: 77951584554     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1245203     Document Type: Article

References (15)

1. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431 (Pubitemid 44511557)
2. Heier J S., Antoszyk A N., Pavan P R. et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006 113 633 e631-634
3. Brown D M., Kaiser P K., Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444 (Pubitemid 44511558)
4. Regillo C D., Brown D M., Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008 145 239-248
5. th EURETINA Congress Vienna, Austria 2008
6. Fung A E., Lalwani G A., Rosenfeld P J. et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007 143 566-583
7. Meyer C H EN, Holz F G. et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim mresults from the SUSTAIN trial [abstract]. IOVS 2008 49 E-Abstract 273
8. Lucentis at one year. Available at http: //www.eyeworld.org/printarticle. php?id = 4390. Last updated 13 July 2009
9. Bailey I L., Lovie J E. New design principles for visual acuity letter charts. Am J Optom Physiol Opt 1976 53 740-745
10. Ferris 3 rd F L., Kassoff A, Bresnick G H. et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982 94 91-96 (Pubitemid 12080556)
11. Barbazetto I, Burdan A, Bressler N M. et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment TAP and VIP report No. 2. Arch Ophthalmol 2003 121 1253-1268
12. Moisseiev J, Alhalel A, Masuri R et al. The impact of the macular photocoagulation study results on the treatment of exudative age-related macular degeneration. Arch Ophthalmol 1995 113 185-189
13. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 131 541-560 (Pubitemid 32427660)
14. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999 117 1329-1345
15. Bressler N M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001 119 198-207 (Pubitemid 32147926)